Immunic AG Logo

Immunic AG

IMUX | NDAQ

Overview

Corporate Details

ISIN(s):
US4525EP1011
LEI:
549300R5T12FW5MEQB20
Country:
United States of America
Address:
C/O The Corporation Trust Company, 19801 Wilmington
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

No description available.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Immunic AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-07 12:30
Earnings Release
Immunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corpor…
English 23.5 KB
2025-06-24 12:30
Regulatory News Service
Immunic Reports New, Positive Long-Term Open-Label Extension Data From Phase 2 …
English 15.2 KB
2025-06-05 12:30
Legal Proceedings Report
Immunic Announces Completion of Enrollment for Both Phase 3 ENSURE Trials in Re…
English 18.3 KB
2025-06-02 12:30
Regulatory News Service
Immunic to Participate in Investor, Scientific and Industry Conferences in June
English 13.9 KB

Automate Your Workflow. Get a real-time feed of all Immunic AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Immunic AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN